Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), a pioneering clinical stage biopharmaceutical company dedicated to advancing innovative treatments for brain health disorders, has announced a strategic license agreement with Catalent

Roche today announced the expansion of their Global Business Partnership Agreement with Sysmex. As part of the renewed framework, the companies strengthen their commitment

NeuroBo Pharmaceuticals, Inc. a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has entered into a term sheet with MThera

Tyra Biosciences, Inc.a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor

Alpenglow Biosciences has been awarded a $1.6M grant to develop artificial intelligence (AI) enabled smart microscopy using its patented multi-resolution 3Di platform for 3D spatial biology.

Harrow a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application for VIGAMOX® 0.5%, a fluoroquinolone antibiotic

Astellas Pharma Inc. today announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has accepted the Biologics License Application

Ionis Pharmaceuticals, Inc. today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin

Biosion USA, Inc. a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis.

Today, the U.S. Food and Drug Administration approved RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use for the emergency treatment of known or suspected opioid overdose.